Evidence map›Paper›PMID 42044100›Full record

ArticleJournal of innate immunity2026

sCD126 as An Independent Prognostic Biomarker in Critical COVID-19.

Giorgos Marinakis, Eleni Karakike, Panagiotis Koufargyris, Maria Patrani, Evangelos J Giamarellos-Bourboulis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of innate immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Giorgos MarinakisIntensive Care Unit, Athens General Hospital "Korgialenio-Benakio", Athens, Greece.
Eleni KarakikeClinic of Intensive Care and Pulmonary Diseases, Faculty of Nursing, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Panagiotis Koufargyris4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Maria PatraniIntensive Care Unit, Athens General Hospital "Korgialenio-Benakio", Athens, Greece.
Evangelos J Giamarellos-Bourboulis4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece, egiamarel@med.uoa.gr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBiomarkers to predict response of critical COVID-19 to tocilizumab (TCZ) are under investigation. Serum levels of interleukin (IL)-6 and IL-6 soluble receptors were studied in a cohort of patients all receiving treatment with TCZ.

methodsIn this prospective clinical study, IL-6, soluble (s) CD126 and sgp130 were measured in the serum of 127 patients with critical COVID-19 the first 24 h from start of mechanical ventilation and before start of TCZ treatment. Outcome was expressed as the World Health Organization Clinical Progression Scale (WHO-CPS) by day 28. The primary endpoint was the identification of a cut-off of the biomarkers which can predict WHO-CPS 6 or more by day 28.

resultsStepwise regression analysis with WHO-CPS ≥6 as the outcome and comorbidities, baseline oxygenation and baseline markers of severity showed that sCD126 ≥ 100 ng/mL is independently associated with worse outcome (odds ratio 2.42; 95% confidence intervals 1.05 to 5.63; p: 0.039).

conclusionIn a cohort of patients with critical COVID-19 receiving TCZ, sCD126 was a predictor of 28-day outcome.

Indexed as

Antibodies, Monoclonal, HumanizedCOVID-19Interleukin-6Ki-1 AntigenAgedBiomarkersFemaleHumansMaleMiddle AgedPandemicsPrognosisProspective StudiesReceptors, Interleukin-6SARS-CoV-2Antibodies, Monoclonal, HumanizedBiomarkersIL6 protein, humanInterleukin-6Ki-1 AntigenReceptors, Interleukin-6tocilizumabCOVID-19sCD126Severe pneumoniaTocilizumab

Identifiers

PMID42044100
PMCPMC13318268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.